- Case report
- Open Access
Spontaneous rupture of giant gastric stromal tumor into gastric lumen
© Mehta et al; licensee BioMed Central Ltd. 2005
- Received: 13 October 2004
- Accepted: 15 February 2005
- Published: 15 February 2005
Gastrointestinal stromal tumors (GIST) constitute a large majority of mesenchymal tumors of the gastrointestinal (GI) tract, which express the c-kit proto-oncogene protein, a cell membrane receptor with tyrosine kinase activity. GI stromal tumors of the stomach are usually associated with bleeding, abdominal pain or a palpable mass.
A 75-year-old male presented with upper abdominal pain and palpable mass. Computed tomographic (CT) scan of the abdomen showed a large mass arising in the posterior aspect of fundus, body, and greater curvature of the stomach. Second day after the admission, there was significant reduction in the size of the tumor, clinically as well as radiologically. Endoscopic biopsy showed large bulge in fundus and corpus of the stomach posteriorly with an opening in the posterior part of the corpus, and biopsy from the edge of the opening reveled GIST. Patient underwent curative resection.
Spontaneous ruptured of giant gastric stromal tumor is very rare presentation of stomach GIST. Thorough clinical examination and timely investigation can diagnose rare complication.
- Stromal Tumor
- Gastrointestinal Stromal Tumor
- Imatinib Mesylate
- Mesenchymal Tumor
Gastrointestinal stromal tumors (GIST) are the most common form of mesenchymal tumors arising from the gastrointestinal (GI) wall, mesentery, omentum or retroperitoneum that express the c-kit proto-oncogene protein . This expression of c-kit distinguishes GIST from true leiomyomas, leiomyosarcomas, and other mesenchymal tumors of the GI tract [1, 2]. Stomach (60–70%) and small intestine (20–30%) is the most common site for GIST . Approximately 10–30% of patients with GIST may be asymptomatic. Stomach and small intestinal stromal tumors are usually associated with abdominal pain, GI bleeding or palpable mass. Around 30% of all GISTs are malignant and liver is the most common site for metastasis. Surgical resection is the primary treatment of GIST . The 5-year survival following curative resection ranges from 20–80% [3–7]. Imatinib mesylate, tyrosine kinase inhibitor, is the first effective drug with response rate of 54% in the treatment of metastatic GIST. We report here a case of GIST which presented with rupture in to the gastric lumen.
A 75-year-old diabetic male presented with dull upper abdominal pain of one-week duration. He noticed swelling in left upper abdomen. There was no history of vomiting, fever or gastrointestinal bleeding. He had no significant medical or family history and was non-smoker and non-alcoholic. Physical examination showed a 14 × 10 cm mass palpable in epigastrium and left hypochondrium with minimal intrinsic mobility.
GI stromal tumors express c-kit protein also known as CD 117, and is considered as highly specific marker that differentiates GIST from other mesenchymal tumors such as leiomyomas [8–10]. The majority of GISTs occur in the stomach (60–70%) and small intestine (20–30%) . GIST arises from the stomach, presented with abdominal pain, GI bleeding or palpable mass. Around 20–30% of GISTs detected during surgery for intestinal obstruction or bleeding . Among the diverse clinical presentation of stomach GISTs, spontaneous ruptured in to peritoneal cavity lead to peritonitis , extragastric growth , complicated with hiatus hernia , ruptured of gastric stromal tumor with cystic degeneration presenting as hemoperitoneum , gastric stromal tumor with myxoid degeneration  have been reported in the literature. Our patient had giant gastric GIST, which ruptured into the stomach with dissemination of its necrotic tissue in the stomach. There was no aggravation of the symptoms. Abdominal examination revealed reduction of the size of tumor from 13 × 10 cm to 8 × 6 cm size. Ultrasound abdomen also confirmed 40% reduction in the size of the tumor. Upper endoscopy biopsy from the edge of the opening, posterior wall of the stomach was suggestive of GIST. Since most of the GISTs are submucosal and grow endophytically, preoperative tissue diagnosis is difficult. In our patient biopsy from the edge of the rent and deep inside the opening confirmed diagnosis of GIST preoperatively. Patient underwent complete tumor resection, with uneventful postoperative period.
Assessment of malignant potential of a primary GIST lesion is difficult in many cases; even as small as less than 2 cm size GIST has certain malignant potentials . Currently, there is no single prognostic factor that can be used alone to predict tumor behavior. Biological behavior of tumor also depends on the location; for example, GISTs arising from the small bowel or colon are generally associated with a less favorable outcome than those arising in the stomach . Radiological and surgical factors that have been used to determine malignancy include invasion to adjacent organs; omental or peritoneal seeding; tumor recurrence after surgical resection; or distant metastasis [8, 17]. Pathological factors that determine malignancy are tumor size, mitotic activity, nuclear pleomorphism, degree of cellularity, nuclear to cytoplasmic ratio, and mucosal invasion . Both mitotic activity and tumor size have been identified as the most important factors predicting malignant behavior [3, 9, 19]. In our patient, most of the factors like size of the tumor, local invasion and high mitotic activity indicated high malignant potential.
Imatinib mesylate, competitive inhibitors of certain tyrosine kinases including the intracellular kinases ABL and BCR-ABL fusion proteins present in some leukemia's, and platelet-derived growth factor receptors , is the first effective drug in the treatment of metastatic GIST. Demetri et al  had reported a response rate of 54%, with median time to response is about 13 weeks, in patients with either inoperable or metastatic GISTs treated with a daily dose of 400 mg or 600 me with follow-up of at least 6 months. Even in patients with large tumor, response to imatinib mesylate can occur rapidly . The optimum dose of imatinib mesylate in the treatment of GIST is not yet known. Toxicity increases with increasing dose, with maximum tolerated dose was 800 mg taken for 8 weeks . Role of imatinib mesylate in the treatment of malignant GIST after curative response is still under investigation. Rational of giving imatinib mesylate in our patient following curative resection, was presence of a very large tumor (>10 cm) with local invasion and high mitotic activity (>5/50 HPF).
Spontaneous ruptured of giant gastric stromal tumor is very rare presentation of stomach GIST. Clinical examination and timely investigations can diagnose this rare complication.
Written consent was taken from the patient for publishing his clinical details, CT scan endoscopy and histology photographs
- Miettinen M, Lasota J: Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003, 54: 3-24.PubMedGoogle Scholar
- Behranwala KA, Spalding D, Wotherspoon A, Fisher C, Thompson JA: Small bowel gastrointestinal stromal tumors and ampullary cancer in Type 1 neurofibromatosis. World J Surg Oncol. 2004, 2: 1-10.1186/1477-7819-2-1.PubMed CentralView ArticlePubMedGoogle Scholar
- Carlomagno G, Beneduce P: A gastrointestinal stromal tumor (GIST) masquerading as ovarian mass. World J Surg Oncol. 2003, 2: 15-10.1186/1477-7819-2-15.View ArticleGoogle Scholar
- Besana-Ciani I, Boni L, Dionigi G, Benevento A, Dionigi R: Outcome and long-term results of surgical resection for gastrointestinal stromal tumors (GIST). Scand J Surg. 2003, 92: 195-199.PubMedGoogle Scholar
- Liberati G, Lucchetta MC, Petraccia L, Nocchi S, Rosentzwig R, De Matteis A, Grassi M: Meta-analytical study of gastrointestinal stromal tumors (GIST). Clin Ter. 2003, 154: 85-91.PubMedGoogle Scholar
- Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA: Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002, 20: 3898-3905. 10.1200/JCO.2002.03.095.View ArticlePubMedGoogle Scholar
- Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, Swallow CJ: Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001, 8: 50-59. 10.1245/aso.2001.8.1.50.View ArticlePubMedGoogle Scholar
- Miettinen M, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999, 30: 1213-1220. 10.1016/S0046-8177(99)90040-0.View ArticlePubMedGoogle Scholar
- Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors; a consensus approach. Hum Pathol. 2002, 33: 459-465. 10.1053/hupa.2002.123545.View ArticlePubMedGoogle Scholar
- Miettinen M, Sobin LH, Sarlomo-Rikala M: Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD 117 (KIT). Mod Pathol. 2000, 13: 1134-1142. 10.1038/modpathol.3880210.View ArticlePubMedGoogle Scholar
- Kitabayashi K, Seki T, Kishimoto K, Saitoh H, Ueno K, Kita I, Takashima S, Kurose N, Nojima T: A spontaneously ruptured gastric stromal tumor presenting as generalized peritonitis: report of a case. Surg Today. 2001, 31: 350-354. 10.1007/s005950170159.View ArticlePubMedGoogle Scholar
- Kimura H, Yoshida T, Kinoshita S, Takahashi I: Pedunculated giant gastrointestinal stromal tumor of the stomach showing extragastric growth: report of a case. Surg Today. 2004, 34: 159-162. 10.1007/s00595-003-2659-3.View ArticlePubMedGoogle Scholar
- Miyauchi T, Ishikawa M, Nisioka M, Kashiwagi Y, Miki H, Sato Y, Endo N, Uemura T, Inoue S, Hiroi M, Kikutsuji T, Ohgami N: Giant gastrointestinal stromal tumor, associated with esophageal hiatus hernia. J Med Invest. 2002, 49: 186-192.PubMedGoogle Scholar
- Cheon YK, Jung IS, Cho YD, Kim JO, Lee JS, Lee MS, Kim JH, Hur KY, Jin SY, Shim CS: A spontaneously ruptured gastric stromal tumor with cystic degeneration presenting as hemoperitoneum: a case report. J Korean Med Sci. 2003, 18: 751-755.PubMed CentralView ArticlePubMedGoogle Scholar
- Alvarado-Cabrero I, Ramirez-Balderrama L, Sierra-Santiesteban FI: Gastric stromal tumor with myxoid degeneration. Report of a case and review of the literature. Rev Gastroenterol Mex. 2000, 65: 22-25.PubMedGoogle Scholar
- Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ: Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Am J Surg Pathol. 1999, 23: 82-87. 10.1097/00000478-199901000-00009.View ArticlePubMedGoogle Scholar
- Miettinen M, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumors. Ann Chir Gynaecol. 1998, 87: 278-281.PubMedGoogle Scholar
- Franquemont DW: Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol. 1995, 103: 41-47.PubMedGoogle Scholar
- Miettinen M, El-Rifai W, Sobin LH, Lasota J: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002, 33: 478-483. 10.1053/hupa.2002.124123.View ArticlePubMedGoogle Scholar
- Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997, 90: 4947-4952.PubMedGoogle Scholar
- Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347: 472-480. 10.1056/NEJMoa020461.View ArticlePubMedGoogle Scholar
- van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS, European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group: Safety and efficacy of imatinib mesylate (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet. 2001, 358: 1421-1423. 10.1016/S0140-6736(01)06535-7.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.